Evidence map›Paper›PMID 27713887›Full record

ReviewAnnals of translational medicine2016

New role of biomarkers: mid-regional pro-adrenomedullin, the biomarker of organ failure.

Francisco Valenzuela-Sánchez, Blanca Valenzuela-Méndez, Juan Francisco Rodríguez-Gutiérrez, Ángel Estella-García, María Ángela González-García

Registry-linked trialOpen access · hybridAbstract readReview
In one paragraph

Review in Annals of translational medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06130046 (MR-proADM as a Early Biomarker for DGF and AR in Kidney and Liver Transplantation), which is not on this map. Cited by 49 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 1 pooled it
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06130046 recruitingnot on this mapstarted 2022, after this paper: background citation

MR-proADM as a Early Biomarker for DGF and AR in Kidney and Liver Transplantation

TypeobservationalSponsorUniversity of Rome Tor VergataRan2022 to 2026Enrolled300ConditionsKidney Transplant, Complications, Liver Transplant, ComplicationsArmsMR-proADM dosage
3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 1 synthesis or guideline pooled it, 114 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Pro-adrenomedullin: a novel diagnostic biomarker of acute appendicitis.Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES · 2026
    Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Pregnancy & cardiovascular disease: the PREG-CVD-HH registry.Cardiovascular diagnosis and therapy · 2024
    Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Francisco Valenzuela-SánchezCritical Care Medicine Department, University Hospital SAS of Jerez, Jerez de la Frontera, Spain.
Blanca Valenzuela-MéndezGinecology and Obstetric Department, University Hospital Germans Trias i Pujol, Barcelona, Spain;; Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
Juan Francisco Rodríguez-GutiérrezHematology Department, University Hospital SAS of Jerez, Jerez de la Frontera, Spain.
Ángel Estella-GarcíaCritical Care Medicine Department, University Hospital SAS of Jerez, Jerez de la Frontera, Spain.
María Ángela González-GarcíaClinical Analysis Laboratory, University Hospital SAS of Jerez, Jerez de la Frontera, Spain.
Hospital Jerez Puerta del Sur · ESHospital Universitari Germans Trias i Pujol · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mid-regional pro-adrenomedullin (MR-proADM) has a good biomarker profile: its half-life is several hours, and its plasma concentrations can be determined in clinical practice, it is essentially irrelevant, but proportionally represents the levels and activity of adrenomedullin (ADM). ADM synthesis is widely distributed in tissues, including bone, adrenal cortex, kidney, lung, blood vessels and heart. Its fundamental biological effects include vasodilator, positive inotropic, diuretic, natriuretic and bronchodilator. It has been described high levels in septic patients, interacting directly with the relaxation of vascular tone, triggering hypotension of these patients. It is also found high levels in other diseases such as hypertension, heart failure, respiratory failure, renal failure, cirrhosis and cancer. MR-proADM has been identified as a prognostic marker, stratifying the mortality risk in patients with sepsis in emergency department (ED) and ICU. Evolutionary MR-proADM levels and clearance marker to the 2nd-5th days of admission help to determine the poor performance and the risk of mortality in patients with severe sepsis admitted to the ICU. The MR-proADM levels are more effective than procalcitonin (PCT) and C-reactive protein (CRP) levels to determine an unfavorable outcome and the risk of mortality in patients with sepsis admitted to the ICU. It has also proved useful in patients diagnosed with organ dysfunction of infectious etiology. MR-proADM levels are independent of the germ conversely it is related to the magnitude of organ failure and therefore severity. We consider advisable incorporating the MR-proADM the panel of biomarkers necessary for the diagnosis and treatment of critically ill patients admitted to the ICU with severe sepsis. The combined PCT and MR-proADM levels could represent a valid tool in the clinical practice to timely identify patients with bacterial infections and guide the diagnosis and treatment of sepsis and septic shock.

Indexed as

adrenomedullin (ADM)biomarkerMid-regional pro-adrenomedullin (MR-proADM)sepsisseptic shock

Identifiers

PMID27713887
PMCPMC5050192
OpenAlexW2522448759

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.